Tags : Astellas

Insights+: COVID-19 Healthcare News Monthly Updates – June 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: The US FDA New Drug Approvals in May 2020

The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020. […]Read More

Astellas Reports Results of Roxadustat in P-III DOLOMITES Study to

Shots: The P-III study involves assessing of Roxadustat (N=323) vs darbepoetin alfa (N=293) evaluating its safety and efficacy in (N=616) adult anemia patients with stage 3–5 chronic kidney disease (CKD) The study meet its 1EPs & 2EPs also demonstrated superiority, showing correction of hemoglobin levels during the first 24 wks. (89.5% vs 78.0%), decrease in […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Astellas and FibroGen Report EMA’s Acceptance of MAA for Roxadustat

Shots: The MAA is supported by P-III program which includes 9000+ patients globally and data from DOLOMITES study, results of which will be disclosed this year. Results of P-III program demonstrated that the therapy is efficacious in increasing & maintaining target hemoglobin levels with reduction in the use of IV iron in patients with CKD […]Read More

PharmaShots Weekly Snapshot (April 27 -May 01, 2020)

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis Published: Apr 30, 2020 | Tags: WuXi Biologics, Aravive, Collaborate, Develop, Novel, High-Affinity Bispecific Antibodies, Cancer,  Fibrosis  Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval as a Treatment for Uncontrolled Asthma Published: May 01, 2020 | Tags: Novartis, Enerzair, […]Read More

Astellas Signs a Three-Year Research Alliance with Harvard University Across

Shots: Astellas and Harvard enter into a 3yrs. strategic research collaboration initiated by faculty at Harvard, focused on the research and development of innovative therapeutics and technologies of mutual interest  Astellas will issue one or more challenges, based on the research scopes of Astellas to inspire the research proposals by Harvard faculty. The proposals will […]Read More

PharmaShots Weekly Snapshot (April 06 -10, 2020)

Amgen Signs a Partnership with Adaptive Biotechnologies to Develop for COVID-19 Published: Apr 09, 2020 | Tags: Amgen, Adaptive Biotechnologies, Develop, Abs, COVID-19 2.  Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop Abs for COVID-19 Published: Apr 09, 2020 | Tags: Samsung Biologics, Agreement, Vir Biotechnology, Abs, COVID-19 3.  Abbott’s TriClip Transcatheter Tricuspid […]Read More